# FORM D

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Sing Washington, D.C. 20549

ORIGINA Lail Processing Section

FORM D

1360245

OMB Number: 3235-0076
Expires: June 30, 2008
Estimated average burden
hours per response ....... 16.00

**OMB APPROVAL** 

SEC USE ONLY						
Prefix Serial						
1	1					
DATE RECEIVED						

JUL -9 2008NOTICE OF SALE OF SECURITIES

PURSUANT TO REGULATION D,

SECTION 4(6), AND/OR

110
UNIFORM LIMITED OFFERING EXEMPTION

Name of Offering ( check if this is an amendment and name has changed, and indicated Series C Preferred Stock; Common Stock issuable upon conversion thereof	ate change.)		
Filing Under (Check box(es) that apply):  Rule 504 Rule 505 Rule 506	Section 4(6) ULOE		
Type of Filing: New Filing Amendment	Jaccilon 4(0) G OLOE		
A. BASIC IDENTIFICATION I	DATA		
1. Enter the information requested about the issuer			
Name of Issuer ( check if this is an amendment and name has changed, and indicate InteKrin Therapeutics Inc.	change.)		
Address of Executive Offices (Number and Street, City, State, Zip Code)	Telephone Number (Including Area Code)		
4300 El Camino Real, Suite 201, Los Altos, CA 94022	(650) 941-5501		
Address of Principal Business Operations (Number and Street, City, State, Zip Code) Telephone Number (Including Area Code Same)			
Brief Description of Business			
Development and commercialization of pharmaceuticals			
Type of Business Organization	PROCESSED		
☐ corporation ☐ limited partnership, already formed	other (please specify):		
business trust limited partnership, to be formed	<u>-P&lt; JUL 1 4 2008</u>		
Actual or Estimated Date of Incorporation or Organization:    Month Year	Actual Estimated THOMSON REUTE		
CN for Canada; FN for other foreign juri	sdiction) DE		
GENERAL INSTRUCTIONS			
Federal:			
Who Must File: All issuers making an offering of securities in reliance on an exemp	otion under Regulation D or Section 4(6), 17 CFR 230.501		
et seq. or 15 U.S.C. 77d(6).			
When to File: A notice must be filed no later than 15 days after the first sale of securi			
Securities and Exchange Commission (SEC) on the earlier of the date it is received by			
address after the date on which it is due, on the date it was mailed by United States regist	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \		
Where to File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Wash	nington, D.C. 2		
Copies Required: Five (5) copies of this notice must be filed with the SEC, one of visigned must be photocopies of the manually signed copy or bear typed or printed signature.			

Information Required: A new filing must contain all information requested. Amendments need only rep. .....e of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

#### State

This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires the payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

## **ATTENTION**

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

### A. BASIC IDENTIFICATION DATA 2. Enter the information requested for the following: Each promoter of the issuer, if the issuer has been organized within the past five years; Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer; Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and Each general and managing partner of partnership issuers. Check Box(es) that Apply: Promoter Beneficial Owner ☐ Executive Officer Director General and/or Managing Partner Full Name (Last name first, if individual) Amgen, Inc. Business or Residence Address (Number and Street, City, State, Zip Code) One Amgen Center Drive, Thousand Oaks, CA 91320-1799 Executive Officer General and/or Check Box(es) that Apply: Promoter Beneficial Owner ☐ Director Managing Partner Full Name (Last name first, if individual) Caduceus Private Investments III, LP and related entity Business or Residence Address (Number and Street, City, State, Zip Code) c/o OrbiMed Advisors, LLC, 767 Third Avenue, Thirtieth Floor, New York, NY 10017 Check Box(es) that Apply: Promoter ⊠ Beneficial Owner ☐ Executive Officer ☐ Director General and/or Managing Partner Full Name (Last name first, if individual) Lanfear, Dennis M., as Trustee of the Lanfear Revocable Trust, dated January 27, 2004, as restated Business or Residence Address (Number and Street, City, State, Zip Code) c/o InteKrin Therapeutics Inc., 4300 El Camino Real, Suite 201, Los Altos, CA 94022 Check Box(es) that Apply: Promoter Beneficial Owner ☐ Executive Officer ☐ Director General and/or Managing Partner Full Name (Last name first, if individual) Skyline Venture Partners V, L.P. Business or Residence Address (Number and Street, City, State, Zip Code) Skyline Ventures, 525 University Avenue, Suite 502, Palo Alto, CA 94301 Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer ☐ Director General and/or Managing Partner Full Name (Last name first, if individual) Sofinnova Venture Partners VII, L.P. Business or Residence Address (Number and Street, City, State, Zip Code) c/o Sofinnova Venture Partners, 140 Geary Street, Tenth Floor, San Francisco, CA 94108-5630 Beneficial Owner ☐ General and/or Check Box(es) that Apply: Promoter Executive Officer □ Director Managing Partner Full Name (Last name first, if individual) Brand, David M. Business or Residence Address (Number and Street, City, State, Zip Code) c/o InteKrin Therapeutics Inc., 4300 El Camino Real, Suite 201, Los Altos, CA 94022 Check Box(es) that Apply: Promoter ☐ Beneficial Owner ☐ General and/or Executive Officer □ Director Managing Partner Full Name (Last name first, if individual) Freed, M.D., FACP, Martin I. Business or Residence Address (Number and Street, City, State, Zip Code) c/o InteKrin Therapeutics Inc., 4300 El Camino Real, Suite 201, Los Altos, CA 94022 (Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

2 of 9

## A. BASIC IDENTIFICATION DATA 2. Enter the information requested for the following: Each promoter of the issuer, if the issuer has been organized within the past five years; Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer; Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and Each general and managing partner of partnership issuers. □ Executive Officer □ Director General and/or Check Box(es) that Apply: Promoter Beneficial Owner Managing Partner Full Name (Last name first, if individual) Healy, M.D., Ph.D., James I. Business or Residence Address (Number and Street, City, State, Zip Code) c/o Sofinnova Venture Partners, 140 Geary Street, Tenth Floor, San Francisco, CA 94108-5630 Check Box(es) that Apply: Promoter ⊠ Beneficial Owner □ Director General and/or Managing Partner Full Name (Last name first, if individual) Lanfear, Dennis M. Business or Residence Address (Number and Street, City, State, Zip Code) InteKrin Therapeutics Inc., 4300 El Camino Real, Suite 201, Los Altos, CA 94022 Check Box(es) that Apply: Promoter Beneficial Owner □ Executive Officer □ Director General and/or Managing Partner Full Name (Last name first, if individual) Lowe, David G. Business or Residence Address (Number and Street, City, State, Zip Code) c/o Skyline Ventures, 525 University Avenue, Suite 502, Palo Alto, CA 94301 Beneficial Owner ☐ Executive Officer □ Director General and/or Managing Partner Full Name (Last name first, if individual) Sears, Lowell E. Business or Residence Address (Number and Street, City, State, Zip Code) c/o Sears Capital Management, Inc., 300 Third Street, Second Floor, Suite 6, Los Altos, CA 94022 Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer □ Director General and/or Managing Partner Full Name (Last name first, if individual) Selick, Ph.D., Harold E. Business or Residence Address (Number and Street, City, State, Zip Code) c/o InteKrin Therapeutics Inc., 4300 El Camino Real, Suite 201, Los Altos, CA 94022 Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer □ Director ☐ General and/or Managing Partner Full Name (Last name first, if individual) Wertheimer, Ph.D., Samuel P. Business or Residence Address (Number and Street, City, State, Zip Code) c/o OrbiMed Advisors, LLC, 767 Third Avenue, Thirtieth Floor, New York, NY 10017 Check Box(es) that Apply: Promoter Beneficial Owner ☐ Executive Officer General and/or ☐ Director Managing Partner Full Name (Last name first, if individual) Business or Residence Address (Number and Street, City, State, Zip Code) (Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

3 of 9

1. Has the issuer sold, or does the issuer intend to sell, to non-accredited investors in this offering?  Answer also in Appendix, Column 2, if filing under ULOE.  2. What is the minimum investment that will be accepted from any individual?  \$3.315	No S No
Yes	No.
4. Enter the information requested for each person who has been or will be paid or given, directly or indirectly, any commission or similar remuneration for solicitation of purchasers in connection with sales of securities in the offering. If a person to be listed is an associated person or agent of a broker or dealer registered with the SEC and/or with a state or states, list the name of the broker or dealer. If more than five (5) persons to be listed are associated persons of such a broker or dealer, you may set forth the information for that broker or dealer only.	
Full Name (Last name first, if individual)	
Business or Residence Address (Number and Street, City, State, Zip Code)	
Name of Associated Broker or Dealer	
States in Which Person Listed Has Solicited or Intends to Solicit Purchasers	
(Check "All States" or check individual States)	☐ All States
[AL] [AK] [AZ] [AR] [CA] [CO] [CT] [DE] [DC] [FL] [GA] [HI]	[ID]
(IL) [IN] [IA] [KS] [KY] [LA] [ME] [MD] [MA] [MI] [MN] [MS]	[MO]
[MT] [NE] [NV] [NH] [NJ] [NM] [NY] [NC] [ND] [OH] [OK] [OR] [RI] [SC] [SD] [TN] [TX] [UT] [VT] [VA] [WA] [WV] [WI] [WY]	[PA] [PR]
Full Name (Last name first, if individual)	
Business or Residence Address (Number and Street, City, State, Zip Code)	
Name of Associated Broker or Dealer	<del></del>
States in Which Person Listed Has Solicited or Intends to Solicit Purchasers	
(Check "All States" or check individual States)	All States
[AL] [AK] [AZ] [AR] [CA] [CO] [CT] [DE] [DC] [FL] [GA] [HI]	[ID]
[IL] [IN] [IA] [KS] [KY] [LA] [ME] [MD] [MA] [MI] [MN] [MS]	[MO]
[MT] [NE] [NV] [NH] [NJ] [NM] [NY] [NC] [ND] [OH] [OK] [OR] [RI] [SC] [SD] [TN] [TX] [UT] [VT] [VA] [WA] [WV] [WI] [WY]	[PA] [PR]
Full Name (Last name first, if individual)	[1 K]
·	
Business or Residence Address (Number and Street, City, State, Zip Code)	
Name of Associated Broker or Dealer	
States in Which Person Listed Has Solicited or Intends to Solicit Purchasers (Check "All States" or check individual States)	☐ All States
[AL] [AK] [AZ] [AR] [CA] [CO] [CT] [DE] [DC] [FL] [GA] [HI]	[ID]
[IL] [IN] [IA] [KS] [KY] [LA] [ME] [MD] [MA] [MI] [MN] [MS]	[MO]
[MT] (NE) [NV] [NH] [NJ] [NM] [NY] [NC] [ND] [OH] [OK] [OR] [RI] [SC] [SD] [TN] [TX] [UT] [VT] [VA] [WA] [WV] [WI] [WY]	[PA] [PR]

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

ı

#### 1. Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box and indicate in the columns below the amounts of the securities offered for exchange and already exchanged. Aggregate Amount Already Type of Security Offering Price Sold \$0.00 \$18,249,994.13 Common Preferred \$0.00 Partnership Interests \$0.00 \$0.00 \_\_\_\_\_)......\$0.00 Other (Specify \$0.00 \$18,249,994,13 Answer also in Appendix, Column 3, if filing under ULOE. 2. Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero." Aggregate Number Dollar Amount Investors of Purchases Accredited Investors 12 \$18,249,994.13 Non-accredited Investors 0 \$0.00 Total (for filings under Rule 504 only) Answer also in Appendix, Column 4, if filing under ULOE. If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C - Question 1. Type of **Dollar Amount** Type of offering Security Sold Rule 505 ..... Regulation A ..... Total ..... 4. a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate. Transfer Agent's Fees..... \$0.00 Printing and Engraving Costs $\Box$ \$0.00 $\boxtimes$ Legal Fees ..... \$75,000.00 Accounting Fees..... \$0.00 Engineering Fees \$0.00 Sales Commissions (specify finders' fees separately) \$0.00 Other Expenses (identify) Blue Sky Filing Fees \$1,050.00

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS

Total .....

\$76,050.00

 $\boxtimes$ 

	C, OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES A	ND USE C	OF PROCEEDS		
	b. Enter the difference between the aggregate offering price given in response to Part C - Ques and total expenses furnished in response to Part C - Question 4.a. This difference is the "adjusted proceeds to the issuer."	gross			\$26,064,316.74
5.	Indicate below the amount of the adjusted gross proceeds to the issuer used or proposed to be used for e the purposes shown. If the amount for any purpose is not known, furnish an estimate and check the box left of the estimate. The total of the payments listed must equal the adjusted gross proceeds to the issuforth in response to Part C - Question 4.b above.				
			Payments to Officers, Directors, & Affiliates		Payments to Others
	Salaries and fees	□ \$0.0	00		\$0.00
	Purchase of real estate	□ \$0.0	<u>00</u>		\$0.00
	Purchase, rental or leasing and installation of machinery and equipment	□ \$0.0	00		\$0.00
	Construction or leasing of plant buildings and facilities	□ <b>\$</b> 0.0	00		\$0.00
	Acquisition of other business (including the value of securities involved in this		<del></del>		
	offering that may be used in exchange for the assets or securities of another				
	issuer pursuant to a merger)	□ <u>\$0.0</u>	00_		<u>\$0.00</u>
	Repayment of indebtedness	□ <u>\$0.0</u>	<u>00</u>		
	Working capital	□ <u>\$0.0</u>	00	$\boxtimes$	\$26,064,316.74
	Other (specify):				
		□ <u>\$0.0</u>	<u>00</u>		<u>\$0.00</u>
	Column Totals	□ \$0.0		_ 🛛	\$26,064,316.74
	Total Payments Listed (column totals added)		<u>\$26,06</u>	-	
	D. FEDERAL SIGNATURE	<del></del>			
Th	e issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this	Spotice is	filed under Rule	505 f	he following
sig	nature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Conformation furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Pule	imission, u	upon written requ	uest of	its staff, the
	tuer (Print or Type)  Signature  MteKrin Therapeutics Inc		Date 7, 2008	•	
Na	time of Signer (Print or Type) Title of Signer (Print or Type)				<del></del>
D	ennis M. Lanfear President, Chief Executive Officer and Secreta	ary			
					<del></del>

**ATTENTION** 

Intentional misstatements or omissions of fact constitute federal criminal violations. (See 18 U.S.C. 460)